Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 2 · 40%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 2 · 40%High 0 · 0%

Change in neuropathy symptoms · people with DPN

1 finding from 1 review

Alpha‐lipoic acid for diabetic peripheral neuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 330 participants
Moderate

Change in impairment 1 to 14 days after the start of treatment ‐ not reported · people with DPN

1 finding from 1 review

Alpha‐lipoic acid for diabetic peripheral neuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 245 participants
Low

Change in any validated quality of life score · people with DPN

The review found no eligible studies for this question.

1 finding from 1 review

Alpha‐lipoic acid for diabetic peripheral neuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Complications of DPN · people with DPN

The review found no eligible studies for this question.

1 finding from 1 review

Alpha‐lipoic acid for diabetic peripheral neuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Withdrawals due to adverse events · people with DPN

Alpha‐lipoic acid showed no clear difference in adverse events leading to cessation of treatment compared with placebo (moderate certainty).

1 finding from 1 review

Alpha‐lipoic acid for diabetic peripheral neuropathy 2024 · Cochrane Headline outcomes only
RR 1.48 [0.5, 4.35]
3 studies · 1090 participants
Moderate